- Centene Corporation (NYSE:CNC) has agreed to sell Magellan Rx to Prime Therapeutics LLC and PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners.
- Centene expects to receive approximately $2.8 billion in aggregate proceeds from the transactions.
- Magellan Rx is a comprehensive pharmacy solutions organization with specialty drug management, Medicaid administration, and comprehensive pharmacy benefits management capabilities.
- Centene acquired Magellan Rx in January 2022 as part of its acquisition of Magellan Health, Inc.
- PANTHERx is a specialty pharmacy. Centene acquired PANTHERx in December 2020.
- Centene will use most of the net proceeds from the sales to repurchase stock and the balance to reduce debt.
- Each transaction is expected to be neutral to slightly accretive to Centene's Adjusted Earnings Per Share in 12 months post-closing.
- The company closed the March quarter with long-term debt of 18.64 billion.
- Price Action: CNC shares are up 0.93% at $83.67 during the market session on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Centene Offloads Two Pharmacy Businesses For $2.8B
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks